# BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)

> **NCT00887601** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 32 (actual)

## Conditions studied

- Dementia

## Interventions

- **DRUG:** MK3134
- **DRUG:** Comparator: Placebo
- **DRUG:** Donepezil
- **DRUG:** MK3134

## Key facts

- **NCT ID:** NCT00887601
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00887601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00887601, "BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00887601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*